Pharmstandard 2013 AR2
The report highlights Pharmstandard's performance in 2013, marking its 10th anniversary with a 10% revenue increase to RUB 56 billion. A key strategic milestone was the reorganization and spin-off of its branded over-the-counter business into a separate company, OTCPharm PJSC. The company also completed the acquisition of Bever Pharmaceutical PTE LTD to secure a long-term supply of active pharmaceutical ingredients. Additionally, Pharmstandard launched 11 new drugs and continued its focus on prescription products and production localization.
Company: Pharmstandard
Sector: Manufacturing
Country: Russia
Year: 2013
Type: AR2
Pages: 125
Back to company
Pharmstandard
Annual Report
The report highlights Pharmstandard's performance in 2013, marking its 10th anniversary with a 10% revenue increase to RUB 56 billion. A key strategic milestone was the reorganization and spin-off of its branded over-the-counter business into a separate company, OTCPharm PJSC. The company also completed the acquisition of Bever Pharmaceutical PTE LTD to secure a long-term supply of active pharmaceutical ingredients. Additionally, Pharmstandard launched 11 new drugs and continued its focus on prescription products and production localization.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Jan 1, 2013 - Dec 31, 2013
Fiscal Year
2013
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees